Revium Rx Advances Therapeutic Frontiers with LipoVation Acquisition
Deal News | Feb 04, 2025 | Globenewswire
In a strategic move to reinforce its position in advanced drug delivery technologies, Revium Rx has announced the completion of its acquisition of LipoVation Ltd., an Israeli company specializing in lipid-based nano/micro particle medicines. LipoVation, known for its pioneering work under Prof. Yehezkel Barenholz, becomes a wholly owned subsidiary of Revium Rx, which is set to leverage this acquisition to advance its portfolio of innovative therapeutics for combating drug-resistant infections, enhancing cancer immunotherapies, and developing new immunization techniques. The acquisition aligns with Revium Rx’s strategic focus on nanoparticle-based therapeutics, building on proprietary systems for targeted drug delivery, optimized bioavailability, and controlled release technologies. Leadership changes see David Akunis appointed as CEO, directing the company's new innovation-focused trajectory, while former CEO Inna Martin transitions to COO and President, emphasizing product development and clinical trials. The acquisition underscores Revium Rx’s commitment to transforming treatment paradigms for challenging diseases through groundbreaking drug delivery solutions.
Sectors
- Pharmaceuticals
- Biotechnology
Geography
- Israel – LipoVation Ltd., the acquired company, is based in Israel.
- United States – Revium Rx, the acquiring company, is based in the United States.
Industry
- Pharmaceuticals – The acquisition focuses on drug development and innovative therapeutics, which is central to the pharmaceutical industry.
- Biotechnology – LipoVation specializes in lipid-based nano/micro particle technologies, a key area within the biotechnology sector.
Financials
- – The article does not specify the financial details of the acquisition deal.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Revium Rx | Acquirer | Company | An advanced drug delivery company focused on nanoparticle-based therapeutics. |
| LipoVation Ltd. | Target | Company | An Israeli development-stage company specializing in lipid-based nano/micro particle medicines. |
| David Akunis | CEO | People | Recently appointed CEO of Revium Rx, overseeing its new strategic direction. |
| Inna Martin | COO | People | Transitioned to COO and President of Revium Rx, focusing on product development and clinical trials. |
| Prof. Yehezkel Barenholz | Inventor/Scientist | People | Inventor of LipoVation's core technology, Doxil. |